OncoSil Medical
Derby Chang is currently a Senior Regulatory Affairs Associate at OncoSil Medical, with previous experience as a Director at Corto Quality. Derby worked as a Quality and Regulatory Manager at Imaxeon and an Electrical Engineer at Polartechnics Limited. At Polartechnics, Derby was responsible for electronic components in the handheld TruScreen probe, PCB design, standards compliance submission, software testing, and user documentation. Prior to this, Derby worked as an Audio Engineer at National Hearing Aids Systems and as an Electrical Engineer at Telectronics. Derby holds a Bachelor's degree in Electrical and Electronics Engineering and a Bachelor of Science in Physics and Pure Mathematics from the University of Sydney.
This person is not in the org chart
OncoSil Medical
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.